U.S. Markets open in 8 hrs 28 mins
  • S&P Futures

    3,673.25
    +8.75 (+0.24%)
     
  • Dow Futures

    30,002.00
    +70.00 (+0.23%)
     
  • Nasdaq Futures

    12,507.25
    +45.00 (+0.36%)
     
  • Russell 2000 Futures

    1,851.60
    +4.40 (+0.24%)
     
  • Crude Oil

    46.46
    +0.82 (+1.80%)
     
  • Gold

    1,842.40
    +1.30 (+0.07%)
     
  • Silver

    24.10
    +0.02 (+0.07%)
     
  • EUR/USD

    1.2152
    +0.0003 (+0.0243%)
     
  • 10-Yr Bond

    0.9200
    0.0000 (0.00%)
     
  • Vix

    21.28
    +0.11 (+0.52%)
     
  • GBP/USD

    1.3450
    -0.0003 (-0.0215%)
     
  • USD/JPY

    103.9420
    +0.0820 (+0.0790%)
     
  • BTC-USD

    19,226.83
    -30.76 (-0.16%)
     
  • CMC Crypto 200

    377.28
    +2.88 (+0.77%)
     
  • FTSE 100

    6,490.27
    +26.88 (+0.42%)
     
  • Nikkei 225

    26,753.56
    -55.81 (-0.21%)
     

Inspire Medical Systems, Inc. to Report Third Quarter 2019 Financial Results on November 5, 2019

MINNEAPOLIS, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the third quarter 2019 after the close of trading on Tuesday, November 5. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

Tuesday, November 5th @ 5:00 p.m. Eastern Time:

Domestic:

877-407-0792

International:

201-689-8263

Conference ID:

13695274

Webcast:

http://public.viavid.com/index.php?id=136408

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact:
Bob Yedid
LifeSci Advisors
inspire@lifesciadvisors.com
646-597-6989